Albanese A, Cassetta E, Carretta D, Bentivoglio A R, Tonali P
Istituto di Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Clin Neuropharmacol. 1995 Oct;18(5):427-34. doi: 10.1097/00002826-199510000-00005.
Apomorphine (1.5 or 3 mg) or placebo was acutely administered to choreic patients affected by Huntington's disease in a double-blind fashion. The patients were evaluated before the administration, and at 15-min intervals for 2 h afterward, by means of a rating scale for Huntington's disease. As compared to baseline, the total score improved by 38.54% after 1.5 mg and by 30.41% after 3 mg; no variations were observed after placebo. Several items of the scale improved after the administration of 1.5 mg. An average 35.25% improvement was observed in items measuring the intensity of chorea (at rest, with arms outstretched, during conversation, and voluntary movements of the limbs); in addition, motor impersistence (as measured by tongue protrusion) and the capability to suppress associated movements (as measured by head movements during saccades) improved by an average of 31.46 and 61%, respectively. Some items of the scale improved after the administration of 3 mg. Items measuring the intensity of chorea improved by an average of 30.41%; in addition, the extent of vertical gaze improved by 63.77%. These data indicate that apomorphine brings about a transient symptomatic improvement of chorea and of other associated clinical features in Huntington's disease. The time course observed for the antichoreic activity is only partially consistent with the antiparkinsonian action of apomorphine.
以双盲方式对患有亨廷顿舞蹈症的舞蹈症患者急性给予阿扑吗啡(1.5毫克或3毫克)或安慰剂。在给药前以及给药后2小时内每隔15分钟,通过亨廷顿舞蹈症评定量表对患者进行评估。与基线相比,1.5毫克阿扑吗啡给药后总分提高了38.54%,3毫克阿扑吗啡给药后总分提高了30.41%;安慰剂给药后未观察到变化。给予1.5毫克阿扑吗啡后,量表的几个项目有所改善。在测量舞蹈症强度(休息时、手臂伸展时、交谈时以及肢体自主运动时)的项目中,平均改善了35.25%;此外,运动不能持续(通过伸舌测量)和抑制关联运动的能力(通过扫视时的头部运动测量)分别平均改善了31.46%和61%。给予3毫克阿扑吗啡后,量表的一些项目有所改善。测量舞蹈症强度的项目平均改善了30.41%;此外,垂直凝视范围改善了63.77%。这些数据表明,阿扑吗啡可使亨廷顿舞蹈症的舞蹈症及其他相关临床特征产生短暂的症状改善。观察到的抗舞蹈症活性的时间进程仅部分与阿扑吗啡的抗帕金森作用一致。